Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 7/20 | 0.54 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.54 |
| ▸ | KDM2B | Q8NHM5 | 4/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6599410 | 0.89 | OPRD1 (0.69) | OPRD1OPRK1OPRM1 | |
| SCHEMBL6599493 | 0.88 | KDM2B (0.46) | KDM2B | |
| SCHEMBL6601930 | 0.85 | OPRD1 (0.53) | OPRD1OPRK1OPRM1 | |
| SCHEMBL7184049 | 0.83 | OPRD1 (0.53) | OPRD1OPRK1OPRM1 | |
| SCHEMBL7184056 | 0.83 | OPRD1 (0.61) | OPRD1OPRK1OPRM1 | |
| SCHEMBL6600784 | 0.82 | CXCR3 (0.41) | OPRK1OPRM1KDM2B | |
| SCHEMBL6599544 | 0.82 | OPRD1 (0.79) | OPRD1OPRK1OPRM1KDM2B | |
| SCHEMBL6170482 | 0.81 | OPRD1 (0.78) | OPRD1OPRK1OPRM1 | |
| SCHEMBL7196680 | 0.80 | OPRD1 (0.49) | OPRD1OPRK1OPRM1 | |
| SCHEMBL7184052 | 0.78 | OPRD1 (0.57) | OPRD1OPRK1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1140835-B1 | 3,3-BIARYLPIPERIDINE AND 2,2-BIARYLMORPHOLINE DERIVATIVES | PFIZER PROD INC (US) | 2004-05-12 | — | — | EP | disclosed |
| US-20040063940-A1 | 3,3-Biarylpiperidine and 2,2-biarylmorpholine derivatives | PFIZER INC | 2004-04-01 | — | — | US | disclosed |
| US-6503905-B1 | Treating nervous system and gastrointestinal disorders; analgesics, antiasthmatics | PFIZER INC | 2003-01-07 | — | — | US | disclosed |
| EP-1140835-A1 | 3,3-BIARYLPIPERIDINE AND 2,2-BIARYLMORPHOLINE DERIVATIVES | Pfizer Products Inc. (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000039091-A1 | 3,3-BIARYLPIPERIDINE AND 2,2-BIARYLMORPHOLINE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2000-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063940-A1 | 3,3-Biarylpiperidine and 2,2-biarylmorpholine derivatives | BCHE, HTR3C, CHRM2 | OPRD1 24/4885OPRK1 39/4885OPRM1 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.